1. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents: PROLONGED SURVIVAL OBSERVED IN 133 MDS PATIENTS TREATED WITH ORAL DECITABINE/CEDAZURIDINE. (September 2021) Authors: Savona, M.; Mccloskey, J.; Griffiths, E.; Yee, K.; Al-Kali, A.; Zeidan, A.M.; Deeg, H.J.; Patel, P.; Sabloff, M.; Keating, M.-M.; Dao, K.-H.; Zhu, N.; Gabrail, N.; Fazal, S.; Maly, J.; Odenike, O.; Kantarjian, H.; Dezern, A.; O'Connell, C.; Roboz, G. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. (May 2023) Authors: Savona, M.; Mccloskey, J.; Griffiths, E.; Yee, K.; Zeidan, A.; Al-Kali, A.; Deeg, H.J.; Patel, P.; Sabloff, M.; Keating, M.-M.; Zhu, N.; Gabrail, N.; Fazal, S.; Maly, J.; Odenike, O.; Kantarjian, H.; Dezern, A.; O'Connell, C.; Roboz, G.; Busque, L. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗